HOME >> BIOLOGY >> NEWS
Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax

Anthrax vaccine administered in combination with a short course of antibiotics completely protected nonhuman primates from inhalational anthrax, the most lethal form of the disease, according to scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

In a collaborative study involving USAMRIID and the National Institute of Allergy and Infectious Diseases (NIAID), investigators demonstrated that postexposure vaccination can shorten the duration of antibiotic treatment required to protect against inhalational anthrax. The findings, which appear in this week's online edition of Proceedings of the National Academy of Sciences, could have important implications for public health management of anthrax bioterrorism events.

Anthrax is caused by the spore-forming bacterium Bacillus anthracis, and causes three types of disease--cutaneous, gastrointestinal, and inhalational--depending upon the route of exposure. Inhalational anthrax--the type likely to occur following a bioterrorist attack--is difficult to diagnose early, and despite antibiotic therapy, has a high fatality rate. In addition, because anthrax spores can remain in the body for extended periods, antibiotic treatment is typically recommended for 60 days or more following exposure.

As noted by the authors, following the 2001 anthrax attacks in the United States, approximately 10,000 people were offered 60 days of antibiotic therapy to prevent inhalational anthrax. Adverse events associated with this regimen--including diarrhea, nausea, vomiting, and dizziness--were commonly reported. More importantly, only about 44 percent of people completed the whole 60-day course. Thus, minimizing the duration of postexposure antibiotic treatment could be crucial to a successful defense against a large-scale anthrax attack.

In the study, two groups of rhesus macaques were exposed to very high amounts of anthrax spores by aerosol. Both groups were then given c
'"/>

Contact: Caree Vander Linden
Caree.Vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
1-May-2006


Page: 1 2 3

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine hope for sufferers of potentially fatal stomach bug
5. Vaccine to cope with viral diversity in HIV
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
8. Vaccine-producing plant-factories
9. HPV Vaccine: Whats next
10. Vaccine shown effective against chancroid
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received ... innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned ... syringe. The company’s solutions are the first Wharton’s jelly allograft product to be recognized ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... therapeutics product portfolio with a near term focus on Type 2 diabetes and ... commercialization experience across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin ...
(Date:7/18/2020)... ... , ... Commercial launch readiness is a critical stage in a product life ... vaccine, the global economic downturn will only increase price pressures overall for the industry. ... full value from every product launch is critical. However, history shows that only a ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem ... 200 million stem cells. Depending on the patient's condition, treatment may be offered IV, ... die having some form of Alzheimers dementia, and the incidence continues to increase as ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of ... businesses of all types to ensure cleanliness, distancing and occupancy with its patent pending ... Space™ enabled business will provide a health performance index system that scores all aspects ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, a leading ... use of proprietary clean viral vectors, recently announced a key manufacturing agreement with ... platform is the world’s most successful gene therapy delivery vehicle (vector) with broad ...
Breaking Biology Technology:
Cached News: